DiaMedica Therapeutics Inc.
DMAC
$3.53
-$0.01-0.28%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -6.53% | 2.04% | 7.39% | 27.93% | 32.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.46% | 24.33% | 28.92% | 34.41% | 51.90% |
| Operating Income | -25.46% | -24.33% | -28.92% | -34.41% | -51.90% |
| Income Before Tax | -26.25% | -20.73% | -20.13% | -24.69% | -41.69% |
| Income Tax Expenses | -30.23% | 53.57% | 53.57% | 53.57% | 53.57% |
| Earnings from Continuing Operations | -26.12% | -20.78% | -20.19% | -24.74% | -41.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.12% | -20.78% | -20.19% | -24.74% | -41.72% |
| EBIT | -25.46% | -24.33% | -28.92% | -34.41% | -51.90% |
| EBITDA | -25.45% | -24.32% | -28.92% | -34.44% | -51.95% |
| EPS Basic | 2.46% | 11.25% | 15.63% | 5.26% | -19.23% |
| Normalized Basic EPS | 2.42% | 11.32% | 15.67% | 5.27% | -19.29% |
| EPS Diluted | 2.46% | 11.25% | 15.63% | 5.26% | -19.23% |
| Normalized Diluted EPS | 2.42% | 11.32% | 15.67% | 5.27% | -19.29% |
| Average Basic Shares Outstanding | 24.56% | 32.70% | 42.52% | 33.52% | 22.64% |
| Average Diluted Shares Outstanding | 24.56% | 32.70% | 42.52% | 33.52% | 22.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |